대사체학 시장 규모, 점유율, 성장 분석 : 제품별, 바이오인포매틱스 툴 및 서비스별, 용도별, 적응증별, 최종사용자별, 기업 유형별, 지역별 - 산업 예측(2025-2032년)
Metabolomics Market Size, Share, and Growth Analysis, By Product, By Bioinformatics Tools and Services, By Application, By Indication, By End User, By Company Type, By Region - Industry Forecast 2025-2032
대사체학 시장 규모는 2023년에 41억 달러로 평가되며, 2024년 46억 7,000만 달러에서 2032년에는 131억 2,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 13.8%로 성장할 전망입니다.
대사체학 시장은 정밀의료의 도입 증가와 만성질환 진단 방법의 발전으로 인해 큰 성장이 예상됩니다. 주요 촉진요인으로는 제약 부문의 R&D 투자 증가, 분석 기술, 특히 핵자기 공명 분광법 및 질량분석법의 발전으로 다양한 생체 시료의 대사 산물을 종합적으로 분석할 수 있게 되었습니다는 점을 꼽을 수 있습니다. 이러한 고도화를 통해 당뇨병, 심장병, 암과 같은 질병과 관련된 대사이상에 대한 이해가 깊어지고 있습니다. 개인의 대사 시그니처를 밝혀냄으로써 대사체학은 맞춤형 의료를 촉진하고, 더 나은 질병 예측과 개별화된 관리 전략을 가능하게 합니다. 연구를 통해 새로운 대사산물과 상호작용이 발견됨에 따라 표적 및 비표적 대사체학 서비스에 대한 수요가 증가하고, 헬스케어 혁신에서 대사체학의 중요성은 더욱 확고해질 것입니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
대사체학 시장 규모 : 제품별 & CAGR(2025-2032)
- 시장 개요
- 대사체학 기기
- 분리 툴
- 가스 크로마토그래피
- 고속 액체 크로마토그래피
- 초고속 액체 크로마토그래피
- 모세관 전기영동
- 탐지 툴
- 핵자기공명(NMR) 분광법
- 질량분석(MS)
- 표면 기반 질량분석
대사체학 시장 규모 : 바이오인포매틱스 툴과 서비스별 & CAGR(2025-2032)
- 시장 개요
- 바이오인포매틱스 서비스
- 바이오인포매틱스 툴과 데이터베이스
대사체학 시장 규모 : 용도별 & CAGR(2025-2032)
- 시장 개요
- 바이오마커 발견
- Drug Discovery
- 독성 시험
- 영양유전체학
- 기능 유전체학
- 맞춤형 의료
- 기타 용도
대사체학 시장 규모 : 적응증별 & CAGR(2025-2032)
- 시장 개요
- 암
- 심혈관질환
- 신경질환
- 대사장애
- 선천성 대사이상
- 기타 적응증
대사체학 시장 규모 : 최종사용자별 & CAGR(2025-2032)
- 시장 개요
- 학술연구기관
- 제약·바이오테크놀러지 기업
- 계약 조사기관
- 기타 최종사용자
대사체학 시장 규모 : 기업 유형별 & CAGR(2025-2032)
- 시장 개요
- Tier 1 제약회사
- Tier 2 제약회사
- Tier 3 제약회사
대사체학 시장 규모 : 지역별 & CAGR(2025-2032)
- 북미
- 유럽
- 독일
- 스페인
- 프랑스
- 영국
- 이탈리아
- 기타 유럽 지역
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 개요
- 기업의 상세
- 제품 포트폴리오 분석
- 기업의 부문별 점유율 분석
- 매출의 전년대비 비교(2022-2024)
주요 기업 개요
- Agilent Technologies, Inc.(US)
- Thermo Fisher Scientific, Inc.(US)
- Waters Corporation(US)
- Bruker Corporation(US)
- Shimadzu Corporation(Japan)
- Danaher Corporation(SCIEX)(US)
- PerkinElmer, Inc.(US)
- Merck KGaA(Germany)
- Bio-Rad Laboratories, Inc.(US)
- Metabolon, Inc.(US)
- LECO Corporation(US)
- Human Metabolome Technologies, Inc.(Japan)
- GL Sciences, Inc.(Japan)
- Bioocrates Life Sciences AG(Austria)
- BASF SE(Germany)
- MS-OMICS(Various locations)
- Afekta Technologies Ltd.(Finland)
- DNA Xperts Private Limited.(India)
- Metabolomic Technologies Inc.(Canada)
- Kore Technology Ltd.(UK)
결론과 제안
KSA
Metabolomics Market size was valued at USD 4.1 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 13.12 billion by 2032, growing at a CAGR of 13.8% during the forecast period (2025-2032).
The metabolomics market is poised for significant growth due to its increasing adoption in precision medicine and evolving diagnostics for chronic conditions. Key drivers include rising R&D investments in the pharmaceutical sector and advancements in analytical techniques, particularly nuclear magnetic resonance spectroscopy and mass spectrometry, which enable the comprehensive analysis of metabolites in various biological samples. This sophistication enhances our understanding of metabolic dysregulation associated with diseases like diabetes, heart disease, and cancer. By revealing individual metabolic signatures, metabolomics facilitates tailored medical care, enabling better disease prediction and personalized management strategies. As research uncovers novel metabolites and interactions, the demand for targeted and untargeted metabolomics services is set to rise, solidifying its importance in healthcare innovation.
Top-down and bottom-up approaches were used to estimate and validate the size of the Metabolomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Metabolomics Market Segments Analysis
Global Metabolomics Market is segmented by Product, Bioinformatics Tools and Services, Application, Indication, End User, Company Type and region. Based on Product, the market is segmented into Metabolomics Instruments, Separation Tools and Detection Tools. Based on Bioinformatics Tools and Services, the market is segmented into Bioinformatics Services and Bioinformatics Tools and Databases. Based on Application, the market is segmented into Biomarker discovery, Drug discovery, Toxicology testing, Nutrigenomics, Functional Genomics, Personalized medicine and Other Applications. Based on Indication, the market is segmented into Cancer, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders, Inborn Errors of Metabolism and Other Indications. Based on End User, the market is segmented into Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End Users. Based on Company Type, the market is segmented into Tier 1 Pharmaceutical Companies, Tier 2 Pharmaceutical Companies and Tier 3 Pharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Metabolomics Market
Metabolite profiling within biological matrices plays a crucial role in discovering biomarkers and advancing personalized medicine. Through metabolomics studies, researchers can identify various biomarkers associated with intricate clinical phenotypes across multiple biological systems. This process is instrumental in the development of tailored medical treatments, focusing on optimizing therapeutic effectiveness while addressing potential toxicity issues. By employing metabolomics, healthcare providers can enhance patient outcomes by ensuring that medical interventions are more aligned with individual biological responses, ultimately paving the way for a more personalized approach to healthcare.
Restraints in the Metabolomics Market
The Metabolomics market faces significant restraints due to the rapid increase in high-volume and heterogeneous data generation, which exacerbates the existing complexity surrounding data management. As life science research produces increasingly intricate and multifaceted data, accurately evaluating high-dimensional information becomes a daunting challenge. This heightened complexity is anticipated to hinder the growth of the Metabolomics market, as researchers and organizations struggle to effectively analyze and interpret the data generated. Consequently, the difficulty in managing such complicated datasets may limit advancements and adoption within the sector, ultimately restraining its potential expansion and innovation.
Market Trends of the Metabolomics Market
The Metabolomics market is witnessing a significant upward trend driven by the expanding applications of biomarkers derived from bioinformatics analyses. As healthcare increasingly pivots towards personalized medicine, the identification of novel biomarkers through metabolomics advancements is becoming essential for in-vitro diagnostics, environmental toxicology assessment, and drug discovery processes. Over the past decade, the "omics" revolution has not only enhanced the technical capabilities of metabolomics but also broadened its relevance across various biomedical domains. This growth trajectory is expected to continue, fueled by the rising demand for precision medicine and integrative approaches to health diagnostics, propelling the Metabolomics market into new horizons of innovation and application.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Metabolomics Market Size by Product & Service & CAGR (2025-2032)
- Market Overview
- Metabolomics Instruments
- Separation Tools
- Gas Chromatography
- High-performance Liquid Chromatography
- Ultra-performance Liquid Chromatography
- Capillary Electrophoresis
- Detection Tools
- Nuclear Magnetic Resonance (NMR) Spectroscopy
- Mass Spectrometry (MS)
- Surface-Based Mass Analysis
Global Metabolomics Market Size by Bioinformatics Tools and Services & CAGR (2025-2032)
- Market Overview
- Bioinformatics Services
- Bioinformatics Tools and Databases
Global Metabolomics Market Size by Application & CAGR (2025-2032)
- Market Overview
- Biomarker discovery
- Drug discovery
- Toxicology testing
- Nutrigenomics
- Functional Genomics
- Personalized medicine
- Other Applications
Global Metabolomics Market Size by Indication & CAGR (2025-2032)
- Market Overview
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Metabolic Disorders
- Inborn Errors of Metabolism
- Other Indications
Global Metabolomics Market Size by End User & CAGR (2025-2032)
- Market Overview
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Other End Users
Global Metabolomics Market Size by Company Type & CAGR (2025-2032)
- Market Overview
- Tier 1 Pharmaceutical Companies
- Tier 2 Pharmaceutical Companies
- Tier 3 Pharmaceutical Companies
Global Metabolomics Market Size & CAGR (2025-2032)
- North America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- Europe (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- Brazil
- Rest of Latin America
- Middle East & Africa (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Waters Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bruker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shimadzu Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (SCIEX) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Metabolon, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LECO Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Human Metabolome Technologies, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GL Sciences, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bioocrates Life Sciences AG (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BASF SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MS-OMICS (Various locations)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Afekta Technologies Ltd. (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DNA Xperts Private Limited. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Metabolomic Technologies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kore Technology Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
